Advanced search
Enter a research title, an expert name, a programme code such as ADSTEM, or a patent number such as 10-1172638. Results appear as cards with source links you can check yourself.
3 records for “KDSTEM”
Each record states the study stage, institution and source link.
phase1 · 2023
EHL BIO (Korea)
The hospital's affiliated research centre states IND approval and Phase 1 initiation in 2023, with selection for the KFRM programme in 2022 and 2024. A Phase 1 trial targets safety, not proof of efficacy.
EHL BIO (research page)phase1 · 2024
International trial registries
Focused on safety and eGFR decline in small numbers of participants; no evidence of nephron regeneration.
ClinicalTrials.govPublished profiles contain only details checkable against public sources.
EHL BIO
Stem cell therapeutics research and development team
ADSTEM (atopic dermatitis), KDSTEM (chronic kidney disease), RASTEM (rheumatoid arthritis), PDSTEM (Parkinson's disease) and adipose-derived exosome programmes
EHL BIO — Stem cell treatmentAn EHL doctor or scientist? Submit your real biography and licence for the register.
Submit expert profile